Evacetrapib impacts cholesterol but doesn’t reduce cardiovascular events

Cleveland Clinic researchers studying evacetrapib have shown that despite reducing levels of low-density lipoprotein (LDL, or ‘bad’ cholesterol) by 37 percent and raising levels of high-density lipoprotein (HDL, or ‘good’ cholesterol) by 130 percent, the drug failed to reduce rates of major cardiovascular events, including heart attack, stroke, angina or cardiovascular death. —> Read More